<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745055</url>
  </required_header>
  <id_info>
    <org_study_id>A3921013</org_study_id>
    <nct_id>NCT01745055</nct_id>
  </id_info>
  <brief_title>Co-Administration Of Methotrexate And CP-690,550</brief_title>
  <official_title>A Phase 1, Open Label Study Of The Pharmacokinetics Of Multiple Doses Of Oral CP-690,550 And Single Doses Of Oral Methotrexate In Rheumatoid Arthritis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to estimate the effects of methotrexate (MTX) on the pharmacokinetics
      (PK) of CP-690,550 when administered to subjects with rheumatoid arthritis (RA), to estimate
      the effects of CP-690,550 on the PK of MTX and to evaluate the short-term safety and
      tolerability of co-administration of CP-690,550 and MTX.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
    <description>AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for CP-690,550</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for CP-690,550</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) for CP-690,550</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 ,12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550</measure>
    <time_frame>0 (pre-dose) through 12 hours post-dose on Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CL R) for CP-690,550</measure>
    <time_frame>0 (pre-dose) through 24 hours post-dose on Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CL R) for Methotrexate (MTX)</measure>
    <time_frame>0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CP-690,550 (tofacitinib) 30 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550 (tofacitinib)</intervention_name>
    <description>CP-690,550 30 mg q12h for 5 days</description>
    <arm_group_label>CP-690,550 (tofacitinib) 30 mg q12h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>individual dose of methotrexate (stably dosed)</description>
    <arm_group_label>CP-690,550 (tofacitinib) 30 mg q12h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults diagnosed with moderate to severe RA (Rheumatoid Arthritis)

          -  Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.

          -  Treatment with an oral stable weekly dose of Methotrexate (MTX) (15-25 mg/week,
             administered as a single dose [SD]) for a minimum of 4 doses (4 weeks)

        Exclusion Criteria:

          -  Blood dyscrasias including confirmed: Hemoglobin &lt;9 g/dL or Hematocrit &lt;30%; White
             blood cell count &lt;3.0 x 109/L; Absolute neutrophil count &lt;1.2 x 109/L; Platelet count
             &lt;100 x 109/L

          -  Evidence or history of clinically significant infections within the past 6 months (eg,
             those requiring hospitalization, requiring parenteral antimicrobial therapy, or those
             with recurrent oral or genital herpes, recurrent herpes zoster, or any infection
             otherwise judged by the investigator to have the potential for exacerbation by
             participation in the trial.

          -  Total bilirubin, AST (aspartate aminotransferase) or ALT (alanine aminotransferase)
             more than 1.2 times the upper limit of normal at the Screening visit, or a history of
             clinically significant elevated liver function tests (LFTs) while on current MTX dose
             or chronic liver disease, recent or active hepatitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921013&amp;StudyName=Co-Adminstration%20Of%20Methotrexate%20And%20CP-690%2C550</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>December 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2013</results_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>oral JAK inhibitor</keyword>
  <keyword>methotrexate (MTX)</keyword>
  <keyword>rheumatoid arthritis (RA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methotrexate + CP-690,550</title>
          <description>Single oral dose of methotrexate (MTX) on Day 1 (15-25 milligram [mg], as per local prescribing practice); followed by CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6; followed by single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methotrexate + CP-690,550</title>
          <description>Single oral dose of methotrexate (MTX) on Day 1 (15-25 milligram [mg], as per local prescribing practice); followed by CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6; followed by single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550</title>
        <description>AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
        <population>The pharmacokinetic (PK) analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550</title>
          <description>AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).</description>
          <population>The pharmacokinetic (PK) analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>nanogram*hour/milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1370" spread="423"/>
                    <measurement group_id="O2" value="1410" spread="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed, AUC (0-12) of CP-690,550 was analyzed using mixed effect model with treatment as fixed effects and participant as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Adjusted Geometric Means</param_type>
            <param_value>103.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.00</ci_lower_limit>
            <ci_upper_limit>107.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for CP-690,550</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
        <population>The PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for CP-690,550</title>
          <population>The PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375" spread="91.6"/>
                    <measurement group_id="O2" value="384" spread="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed, Cmax of CP-690,550 was analyzed using mixed effect model with treatment as fixed effects and participant as a random effect. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Adjusted Geometric Means</param_type>
            <param_value>102.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.79</ci_lower_limit>
            <ci_upper_limit>112.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of MTX on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)</title>
          <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).</description>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1850" spread="685"/>
                    <measurement group_id="O2" value="1720" spread="753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed, AUClast of MTX was analyzed using mixed effect model with treatment as fixed effects and participant as a random effect. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Adjusted Geometric Means</param_type>
            <param_value>89.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.38</ci_lower_limit>
            <ci_upper_limit>103.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)</title>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of methotrexate (MTX) on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478" spread="106"/>
                    <measurement group_id="O2" value="433" spread="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed, Cmax of MTX was analyzed using mixed effect model with treatment as fixed effects and participant as a random effect. The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Adjusted Geometric Means</param_type>
            <param_value>87.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.03</ci_lower_limit>
            <ci_upper_limit>100.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Decay Half-Life (t1/2) for CP-690,550</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2) for CP-690,550</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.</description>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="0.356"/>
                    <measurement group_id="O2" value="3.12" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) for CP-690,550</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) for CP-690,550</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23200" spread="8380"/>
                    <measurement group_id="O2" value="23511" spread="8784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)</title>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 ,12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of methotrexate (MTX) on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.50" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of MTX on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.</description>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.962"/>
                    <measurement group_id="O2" value="3.36" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) for Methotrexate (MTX)</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of methotrexate (MTX) on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) for Methotrexate (MTX)</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>mL/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9890" spread="3370"/>
                    <measurement group_id="O2" value="11500" spread="5430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550</title>
        <time_frame>0 (pre-dose) through 12 hours post-dose on Day 6 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="2.26"/>
                    <measurement group_id="O2" value="6.58" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CL R) for CP-690,550</title>
        <time_frame>0 (pre-dose) through 24 hours post-dose on Day 6 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,500</title>
            <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CL R) for CP-690,550</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>litre/hour (L/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5490" spread="2890"/>
                    <measurement group_id="O2" value="5240" spread="2630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)</title>
        <time_frame>0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of MTX on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>milligram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="9.31"/>
                    <measurement group_id="O2" value="13.2" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (CL R) for Methotrexate (MTX)</title>
        <time_frame>0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7</time_frame>
        <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>Methotrexate</title>
            <description>Single oral dose of methotrexate (MTX) on Day 1 (15-25 milligram [mg], as per local prescribing practice).</description>
          </group>
          <group group_id="O2">
            <title>Methotrexate + CP-690,500</title>
            <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CL R) for Methotrexate (MTX)</title>
          <population>PK analysis population included all enrolled participants with PK parameters of interest for at least 1 period of fixed sequence.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="4.56"/>
                    <measurement group_id="O2" value="8.95" spread="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Methotrexate</title>
          <description>Single oral dose of MTX on Day 1 (15-25 mg), as per local prescribing practice.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,500</title>
          <description>CP-690,500 30 mg tablet orally every twelve hours from Day 3 to Day 6.</description>
        </group>
        <group group_id="E3">
          <title>Methotrexate + CP-690,500</title>
          <description>Single oral dose of MTX (15-25 mg, as per local prescribing practice) and single oral dose of CP-690,500 30 mg tablet orally, on Day 7.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Migrane</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results were summarized for Ae(0-12) instead of planned Ae(0-24), as CP-690,550 was administered every 12 hours.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

